Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …

The endocannabinoid system (ECS) is composed of two G protein-coupled receptors
(GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid …

The recent identification of cannabinoid receptors and their endogenous lipid ligands has
triggered an exponential growth of studies exploring the endocannabinoid system and its …

Most neurodegenerative disorders (NDD s) are characterized by cognitive impairment and
other neurological defects. The definite cause of and pathways underlying the progression …

The identification of the human cannabinoid receptors and their roles in health and disease,
has been one of the most significant biochemical and pharmacological advancements to …

Abstract l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic
treatment of Parkinson's disease (PD). However, long-term administration of l-DOPA is …

Neurodegeneration leading to Parkinson's disease (PD) and Alzheimer's disease (AD) has
become a major health burden globally. Current treatments mainly target controlling …

As a consequence of an increasingly aging population, the number of people affected by
neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and …

Cannabinoids have been reported to provide neuroprotection in acute and chronic
neurodegeneration. In this study, we examined whether they are also effective against the …

In the last few decades, endocannabinoids, plant-derived cannabinoids and synthetic
cannabinoids have received growing interest as treatment options in neurodegenerative …